Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery and others.
Follow-Up Questions
¿Quién es el CEO de Vicapsys Life Sciences Inc?
Mr. Federico Pier es el Chief Executive Officer de Vicapsys Life Sciences Inc, se unió a la empresa desde 2019.
¿Qué tal es el rendimiento del precio de la acción VICP?
El precio actual de VICP es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Vicapsys Life Sciences Inc?
Vicapsys Life Sciences Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Vicapsys Life Sciences Inc?
La capitalización bursátil actual de Vicapsys Life Sciences Inc es $0
